Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$27,000.00
SLPI Regulation and its Impact on the Ovarian Tumor Microenvironment
FY 2024-25
Summary
Epithelial ovarian cancer is the deadliest gynecological cancer, with a five-year survival rate of 45%. Understanding the pathways that are involved in ovarian cancer and its progression is crucial for finding alternative treatment methods that will increase survival rates. We have recently discovered that secretory leukocyte protease inhibitor (SLPI) is highly expressed in ovarian cancers and correlated with poor survival, however, it is unclear how SLPI impacts the ovarian tumor microenvironment (TME). My first aim is to determine SLPI impact on chemoresistance by treating SLPI-modified cells with standard chemotherapeutic drugs used in ovarian cancer treatment and measuring corresponding cell viability. My second aim is to establish the mechanism regulating SLPI expression. To achieve this aim, we will use inhibitors to block intermediates of potential signaling pathways in various cancer cell lines. We will then measure consequent SLPI expression to determine which pathway is responsible for the upregulation of SLPI. RNA sequencing analysis will be completed to determine what downstream factors and cell signaling pathways are regulated by SLPI. Lastly, I will investigate how SLPI modulates changes in the TME by injecting SLPI-modified ovarian cancer cell lines into mice and assessing the infiltration and localization of immune cells within the tumors. Given its frequent expression in ovarian tumors, we hypothesize that SLPI plays a critical role in tumor progression. This project will explore SLPI role in ovarian cancer, potentially being used as a novel therapeutic target in future studies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529646
Name
Orfali Helene
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
SLPI Regulation and its Impact on the Ovarian Tumor Microenvironment
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Progression; Cell Differentiation And Proliferation; Epithelial Ovarian Cancer; Immunology; K-Ras; Oncogene; Reproductive Biology; Signal Transduction Pathway; Slpi; Tumour Microenvironment
Abstract
Epithelial ovarian cancer is the deadliest gynecological cancer, with a five-year survival rate of 45%. Understanding the pathways that are involved in ovarian cancer and its progression is crucial for finding alternative treatment methods that will increase survival rates. We have recently discovered that secretory leukocyte protease inhibitor (SLPI) is highly expressed in ovarian cancers and correlated with poor survival, however, it is unclear how SLPI impacts the ovarian tumor microenvironment (TME). My first aim is to determine SLPI impact on chemoresistance by treating SLPI-modified cells with standard chemotherapeutic drugs used in ovarian cancer treatment and measuring corresponding cell viability. My second aim is to establish the mechanism regulating SLPI expression. To achieve this aim, we will use inhibitors to block intermediates of potential signaling pathways in various cancer cell lines. We will then measure consequent SLPI expression to determine which pathway is responsible for the upregulation of SLPI. RNA sequencing analysis will be completed to determine what downstream factors and cell signaling pathways are regulated by SLPI. Lastly, I will investigate how SLPI modulates changes in the TME by injecting SLPI-modified ovarian cancer cell lines into mice and assessing the infiltration and localization of immune cells within the tumors. Given its frequent expression in ovarian tumors, we hypothesize that SLPI plays a critical role in tumor progression. This project will explore SLPI role in ovarian cancer, potentially being used as a novel therapeutic target in future studies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Orfali, Helene
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~